**SUPPORTING STATEMENT**

**Part B**

**Survey of Cancer Experiences**

**April 19, 2011**

Agency for Healthcare Research and Quality (AHRQ)

Table of Contents

[B. STATISTICAL METHODS 3](#_Toc277862068)

[1. Potential Respondent Universe and Sample Selection Method 3](#_Toc277862069)

[2. Information Collection Procedures 3](#_Toc277862070)

[3. Methods to Maximize Response Rate 4](#_Toc277862071)

[4. Tests of Procedures 4](#_Toc277862072)

[5. Statistical Consultation and Independent Review 4](#_Toc277862073)

# B. STATISTICAL METHODS

## 1. Potential Respondent Universe and Sample Selection Method

The potential respondent universe will be all residents of the metropolitan Washington, D.C. area and surrounding areas who currently have cancer or who have had cancer in the past. A pre screener will be administered to all those who respond to the recruitment advertisement. A purposive sample of 60 respondents will be recruited through contacts with various cancer support groups such as the American Cancer Society and the Lance Armstrong Foundation. Additional recruiting support will be provided by NCI. If needed, ads will be placed in newspapers or posted in community centers, grocery stores, etc.

To adequately test all of the questions, a mix of respondents with the following characteristics will be recruited:

* Cancer status (currently have cancer; currently not in treatment for cancer)
* Time since treatment (1 year from treatment; 2-5 years from treatment; 6+ years cancer-free)
* Employment status (currently employed; not currently employed)
* Recurrence (recurrence of same cancer type; experienced multiple cancer types)

Sixteen of the respondents will be Spanish speaking and will be recruited to test the Spanish translation of the SAQ in Round 2, using the same recruiting sources as just described.

**Table 1. Respondent Recruitment**

|  |  |
| --- | --- |
| **Respondent characteristics** | **Number of respondents** |
|  | **Pretest Round 1** | **Pretest Round 2 English** | **Pretest Round 2 Spanish** | **Total** |
| Current cancer and currently employed | 4 | 3 | 2 | 9 |
| Current cancer and not currently employed | 4 | 3 | 2 | 9 |
| One year from last treatment | 4 | 3 | 3 | 10 |
| Two to five years from last treatment | 4 | 3 | 3 | 10 |
| Six plus years cancer free | 4 | 4 | 3 | 11 |
| Cancer has returned or had more than one type of cancer | 4 | 4 | 3 | 11 |
| **Total** | 24 | 20 | 16 | 60 |

## 2. Information Collection Procedures

We plan to conduct in person interviews for both rounds of cognitive testing to further refine the survey’s items and composites/dimensions. Phone interviews may be conducted if we are unable to meet the target sample numbers using in person interviewing alone. First the respondent will be asked to complete the self-administered questionnaire. Then an interviewer will ask the respondent to explain what they were thinking as they answered the questions. The interviewer will also ask if there were any words or questions that were confusing and if they understood what was being asked. Based on the results of the first round of pretesting, procedures may be revised for Round 2 to include respondent completion of the SAQ and retrospective probing only.

## 3. Methods to Maximize Response Rate

We are using a cash remuneration as noted in #9 in Supporting Statement Part A.

## 4. Tests of Procedures

The procedures for this specific project have not been subjected to testing. However, the contractor, Westat, has conducted many similar projects and is using well established research methods with this project.

## 5. Statistical Consultation and Independent Review

Following individuals have been consulted on the design of the pretest questionnaire:

Doris Lefkowitz, PhD Agency of Healthcare research and Quality

Anita Soni, PhD Agency of Healthcare research and Quality

Kathy Virgo, PhD MBA (American Cancer Society)

Donatus Ekwueme, PhD (Centers for Disease Control and Prevention)

Juan Rodriguez MPH (Centers for Disease Control and Prevention)

Wendy Hicks, MS Westat, Inc.

Gordon Willis, PhD (National Cancer Institute)

Robin Yabroff, PhD, MBA (National Cancer Institute)